MALS-1 genotype does not influence drug-induced seizures in Black Swiss mice
| MALS-1 genotype | Treatment (mg/kg, i.p.) | Seizures (number seized over total) | Latency (sec ± SEM) |
|---|---|---|---|
| Wild type (+/+) | Picrotoxin (8) | 5 /5 | 198 ± 25 |
| Heterozygote (+/−) | Picrotoxin (8) | 7 /7 | 226 ± 30 |
| Homozygote (−/−) | Picrotoxin (8) | 7 /7 | 238 ± 51 |
| Wild type (+/+) | NMDA (120) | 3 /5 | 217 ± 44 |
| Heterozygote (+/−) | NMDA (120) | 12 /18 | 230 ± 20 |
| Homozygote (−/−) | NMDA (120) | 5 /7 | 189 ± 12 |
Juvenile F2 progeny from an initial MALS-1 KO chimera and Black Swiss intercross were given intraperitoneal injections of varying doses of picrotoxin or NMDA and observed for time to seizure onset.